Filana Therapeutics
American pharmaceutical company
Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc., formerly Pain Therapeutics Inc.) is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam (formerly known as PTI-125 and sumifilam) as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice (DOJ) charged an advisor to Cassava Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission (SEC) filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. The DOJ dropped the fraud charges against Wang shortly before trial was scheduled to begin in October 2025 without giving a reason.
This brief starts where responsible research should: with the source description of “Filana Therapeutics” as american pharmaceutical company. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the history & society register because the source frames it as american pharmaceutical company. Its deeper value depends on whether names, dates, institutions and citations support that framing.
Contemporary correspondence, administrative files and participant testimony can test how later narratives organized the event or institution. The source revision retrieved here is dated Aug 23, 2026. The linked authority identifier is Q111982872. None of the 2 selected statements returned an explicit reference. The first chronological checks are 2024 and 2025.
Institutional narratives can privilege the records that survived while minimizing voices that were never formally collected. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Compare institutional narratives with records created by participants and affected communities. Dates and formal titles are useful anchors, but not substitutes for context.
- Event chronology
- Institutional context
- Locating named record creators
Contemporary correspondence, government or organizational records, oral histories and cited historical scholarship.
Three-step research path
- Establish the record: confirm the title “Filana Therapeutics”, its source revision and the description used here.
- Expand the search: follow Filana Therapeutics primary sources, Filana Therapeutics archive and Filana research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Filana Therapeutics”?
- Who created the surviving record, and for what administrative purpose?
- Which voices are present, absent or mediated by the institution?
Search terms from this dossier
This entry incorporates text from “Filana Therapeutics” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.